Medical Benefits of Psychedelics: Ethics and Policy
This paper examines the ethical and policy dimensions of using Schedule I psychedelics, particularly psilocybin, for medical and therapeutic purposes. It critically analyzes the U.S. government's rationale for prohibiting these substances under the Controlled Substances Act, arguing that scheduling decisions have been shaped as much by politics as by science. Drawing on virtue ethics, Rawlsian theory, and feminist ethics, the paper evaluates whether psychedelic-assisted therapy should be normalized, whether societal stigma constitutes a sound ethical objection, and whether psilocybin therapy should become standard practice for terminally ill patients. The paper ultimately argues that a more holistic, multi-framework ethical approach is needed to responsibly integrate psychedelics into modern medicine.
- Government Classification and the Prohibition of Schedule I Drugs: U.S. drug scheduling policy and psychedelic prohibition history
- Virtue Ethics and the Stigma of Hard Drug Use: Virtue ethics critique of societal stigma around hard drugs
- Rawlsian Justice and the Normalization of Psychedelic Therapy: Rawlsian fairness applied to psychedelic therapy normalization
- Feminist Ethics and Psilocybin for Terminally Ill Patients: Feminist and holistic ethics supporting psilocybin end-of-life care
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each section applies a distinct ethical framework — virtue ethics, Rawlsian theory, and feminist ethics — to a specific policy question, demonstrating range and theoretical literacy.
- The paper engages honestly with counterarguments (e.g., that normalizing psychedelics could harm society) before refuting them, which strengthens its credibility.
- The connection drawn between feminist nursing models (such as the Adaptive Model) and psilocybin therapy is an original and well-supported analytical move that grounds abstract ethics in clinical practice.
Key academic technique demonstrated
The paper effectively uses multi-framework ethical analysis — applying different normative theories to the same policy problem to show how conclusions shift depending on the moral lens used. This technique, common in applied ethics writing, prevents oversimplification and acknowledges the genuine complexity of drug policy debates.
Structure breakdown
The paper is organized as a four-part response to distinct but related prompts, moving from legal-scientific critique (drug scheduling), to social ethics (virtue ethics and stigma), to political philosophy (Rawlsian justice), and finally to feminist ethics and healthcare. Each section builds on the previous, culminating in a practical policy recommendation regarding end-of-life care. Citations from the DEA, The Lancet, The New Yorker, and a nursing theory text provide a credible cross-disciplinary foundation.
Government Classification and the Prohibition of Schedule I Drugs
Presently, anxiety is pharmaceutically treated with drugs such as Xanax, Lorazepam, and Diazepam, all of which are Schedule IV substances — and they do not appear to work as effectively as psilocybin. Drugs, substances, and certain chemicals used to make drugs are classified into five distinct categories or schedules depending upon each drug's acceptable medical use and its potential for abuse or dependency. Schedule I drugs are considered to have a high potential for abuse, coupled with a high rate of developing either physical or psychological dependence (DEA, n.d.). The government argues that these drugs cannot be used ethically because they have little or no accepted medical use and the risks associated with them greatly outweigh any potential benefits.
Yet the classification of drugs appears to be as much a political decision as a scientific one. Fifty years ago, recreational use of substances like psilocybin was common in many countries, and governments largely disapproved of this development. The decision to classify this type of drug seemed, at the time, to reflect social engineering or a means of social control more than a scientific consensus. By the mid-1960s, LSD had escaped from the laboratory and swept through the counterculture. In 1970, Richard Nixon signed the Controlled Substances Act and placed most psychedelics on Schedule I, prohibiting their use for any purpose (Pollan, 2015).
Despite these substances becoming more accepted in the medical and psychiatry communities, a significant stigma continues to surround their use in research. Drawing lessons from the 1950s and 1960s, researchers generally remain cautious about how psychedelics are investigated (Morris, 2008). Organizations such as the FDA and the DEA still appear hesitant to approve their use.
Virtue Ethics and the Stigma of Hard Drug Use
Some argue that society does not want to deal with "hard" drugs — even for medical purposes — because doing so would reflect poorly on national character, projecting weakness or dependence. In any society, its leaders and institutions reflect the broader population. It is reasonable to suspect that many people in leadership positions wish to protect others and impose their own views without fully considering the available evidence or the consequences of those decisions.
Deontological theories and ethical principles are, by definition, duty-based. From this perspective, ethical behavior and the fulfillment of moral obligations depend upon the individual's duties. Some may feel that the use of hard drugs for any purpose is inherently unethical and crosses moral lines. Furthermore, these duties — or virtue ethics — are grounded in intentions rather than specific outcomes; they judge morality by examining the nature of actions and the will of agents rather than the results achieved.
From a virtue ethics perspective, it is understandable why someone might believe that banning hard drugs is justified. However, no ethical theory should be considered in isolation or applied universally. Many additional factors should influence such decisions beyond a simple sense of duty. While a deontological approach may be well suited to many situations, it should not dictate matters of health or the direction of medical research. Some hard drugs have the genuine potential to eliminate pain and suffering for millions of patients. Therefore, while it is easy to see why someone might regard a virtue-based approach as justified in this context, a more comprehensive ethical perspective is needed.
References
Andrews, H., & Roy, C. (1991). The Adaptive Model. Norwalk: Appleton and Lange.
DEA. (n.d.). Drug scheduling. Retrieved from U.S. Drug Enforcement Administration: http://www.dea.gov/druginfo/ds.shtml
Morris, K. (2008). Research on psychedelics moves into the mainstream. The Lancet, 1491–1492.
Pollan, M. (2015, February 9). The trip treatment. Retrieved from The New Yorker: http://www.newyorker.com/magazine/2015/02/09/trip-treatment
Create your account
Always verify citation format against your institution’s current style guide requirements.